Webinar on Infex's Phase II lead respiratory drug, RESP-X

On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with…


RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Clinical candidate nominated for COV-X programme

COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…


Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation

Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…


Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

First subject dosed in Phase I study to evaluate safety and tolerability of…


COVID-19 Pandemic Triggers Upsurge in MBL Infections

New research has discovered that the ongoing COVID-19 pandemic has triggered a…


Infex scientists achieve breakthrough to overcome critical priority drug resistant infections

Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…


Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

Alderley Park, Cheshire –  One of the UK’s leading infectious disease biotech…